Organon & Co (OGN) Stock Analysis

Organon & Co (OGN) is a publicly traded company in the HEALTHCARE sector. It trades at $13.39, carries a market capitalization of $3.50B, a price-to-earnings ratio of 14.34. This page summarizes the public market data, fundamentals, and frequently asked questions for OGN, with GNG Research's proprietary safety, quality, and valuation analysis available to members.

Sector: HEALTHCARE - DRUG MANUFACTURERS - GENERAL

Exchange: NYSE

Key Metrics

• Price: $13.39
• Market Cap: $3.50B
• P/E Ratio: 14.34
• EPS: $0.93
• 52-Week High: $13.48
• 52-Week Low: $5.68

Market Sentiment

Organon & Co currently has a Bullish sentiment score of 0.37.

About Organon & Co

Organon & Co. is a Jersey City-based global pharmaceutical company dedicated to advancing women's health through a robust portfolio that includes products in reproductive medicine, contraception, psychiatry, hormone replacement therapy, and anesthesia. With a strong focus on addressing unmet health needs, Organon leverages its deep industry expertise to deliver innovative solutions to global markets. Positioned at the forefront of the increasing demand for women's health interventions, Organo...

GNG Research Analysis

GNG Research scores Organon & Co (OGN) on three proprietary dimensions — a Safety score, a Quality score, and a Valuation score — alongside fair value estimates and buy-price targets for 5,000+ companies. These ratings are reserved for members. Read how the scores are calculated on our methodology page, or see GNG Research plans to unlock the full rating for OGN.

Frequently Asked Questions

Does OGN pay dividends?

Organon & Co (OGN) does not currently pay a regular dividend.

What is OGN's P/E ratio?

Organon & Co has a price-to-earnings (P/E) ratio of 14.34.

What is OGN's market cap?

Organon & Co (OGN) has a market capitalization of $3.50B with a current stock price of $13.39.